TOMI Environmental Solutions announced that it has added roughly a dozen new client partnerships in the compounding pharmacy industry, a sector that is tightening regulatory oversight under USP <797> and USP <800> standards. The new relationships are driven by pharmacies’ need for validated, automated decontamination solutions to meet FDA audit requirements and avoid costly recalls or shutdowns.
The company’s SteraMist iHP system, which uses ionized hydrogen peroxide to create a fog that disinfects surfaces, is positioned as a routine, everyday partner in the 503A and 503B pharmacy segments. By offering a validated, automated solution that can be integrated into routine cleaning protocols, TOMI is targeting a recurring revenue stream that can smooth the volatility of its equipment‑sales‑heavy business model.
TOMI’s financial context underscores the strategic importance of these new partnerships. The company reported a revenue decline in 2025 to $5.64 million from $7.74 million in 2024, a net loss of $3.75 million, and limited cash reserves of $88,000 as of December 31 2025. Management has guided for approximately $12 million in revenue for 2026, roughly double 2025 levels, and has emphasized a shift toward recurring solution sales to improve profitability and cash flow.
"The compounding pharmacy industry is at a crossroads where manual cleaning is no longer sufficient to meet modern FDA expectations. Our growth in this sector, particularly among 503B outsourcers, reflects a shift toward automated, validated technology. The increasing volume of ongoing solution orders proves that our customers view SteraMist not just as a one‑time purchase, but as an essential, everyday partner in maintaining the highest standards of patient safety and regulatory standing," said COO Elissa J. (E.J.) Shane. CEO and Chairman Dr. Halden Shane added, "We are entering 2026 with operational momentum, growing recurring revenue and expanding global customer base and a clear strategy to drive sustainable growth. Our focus remains on execution, converting our pipeline into recognized revenue while continuing to advance the technology platform that makes all of this possible. The pipeline that we have is the strongest we’ve ever had. Our first quarter 2026 revenue is greater than our first quarter of 2025."
The compounding pharmacy market is highly regulated, with USP <797> governing sterile compounding and USP <800> addressing hazardous drug handling. Compliance requires rigorous environmental control and cleanliness; failure to meet these standards can lead to costly recalls or facility shutdowns. TOMI’s technology, EPA‑registered and proven to achieve a 6‑log reduction against a range of pathogens, is positioned to meet these evolving requirements. While the company faces competition from larger incumbents, the high barriers to entry in this niche market provide a tailwind for TOMI’s recurring revenue model. As of April 6 2026, the company’s market capitalization stood at $12.31 million.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.